Metraipolis › archive › dc_2847cb3fd685

The efficacy of low-dose anlotinib as a first-line treatment for frail patients with lung adenocarcinoma and its bridging significance for subsequent… — Europe PMC PMID:40969813

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40969813
DOI
10.3389/fmed.2025.1659090
License (as archived)
solo-consultazione
Archived
2026-11-10T03:57:36.650Z
SHA-256 of the archived text
92f84a2248ad6b69a582a0f0e23dbf9a2d1c07bf2d513843f8fc8404801176b0
Stable URL of this page
https://metraipolis.com/documento/dc_2847cb3fd685

How to cite

The efficacy of low-dose anlotinib as a first-line treatment for frail patients with lung adenocarcinoma and its bridging significance for subsequent… — Europe PMC PMID:40969813 — Europe PMC (en), https://europepmc.org/article/MED/40969813 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2847cb3fd685 (Metraipolis archive dc_2847cb3fd685, sha256 92f84a2248ad6b69a582a0f0e23dbf9a2d1c07bf2d513843f8fc8404801176b0)
BibTeX
@misc{dc2847cb3fd685,
  title = {The efficacy of low-dose anlotinib as a first-line treatment for frail patients with lung adenocarcinoma and its bridging significance for subsequent… — Europe PMC PMID:40969813},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40969813},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2847cb3fd685; sha256 92f84a2248ad6b69a582a0f0e23dbf9a2d1c07bf2d513843f8fc8404801176b0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40969813. Agents can read the archived copy with the MCP tool read_document.